Recent advances in the cannabinoids

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 10, 2004, Pages 1435-1452

  Hertzog, Donald L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Anandamide transporter inhibitor; Cannabinoid; CB1; CB1 agonist; CB1 antagonist; CB2; CB2 agonist; CB2 antagonist; FAAH ihibitor; Fatty acid amide hydrolase (FAAH)

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 CHLORO N [[3 (4 CHLOROPHENYL) 4 PHENYL 2 PYRAZOLIN 1 YL](METHYLAMINO)METHYLENE]BENZENESULFONAMIDE; ACCOMPLIA; AJULEMIC ACID; ANALGESIC AGENT; ANANDAMIDE; ANTIOBESITY AGENT; BAY 387271; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DEXANABINOL; DRONABINOL; FURO[2,3 B]PYRIDINE DERIVATIVE; HETEROCYCLIC COMPOUND; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; NABILONE; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; RIMONABANT; SAB 378; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRAIN INJURY; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; MENTAL DISEASE; METABOLIC DISORDER; NONHUMAN; OBESITY; PAIN; REVIEW; SMOKING CESSATION; SUBSTANCE ABUSE;

EID: 5744223570     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.10.1435     Document Type: Review

References (37)

1. GAONI Y, MECHOULAM R: Isolation, structure, and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. (1964) 86:1646-1647.
2. BARTH F: Cannabinoid receptor agonists and antagonists. Expert Opin. Ther. Patents (1998) 8:301-313.
3. DEVANE WA, DYSARZ FA, JOHNSON MR, MELVIN LS, HOWLETT AC: Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. (1988) 34:605-613.
4. MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365 61-65.
5. DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-1949.
6. MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83-90.
7. SUGIURA T, KONDO S, SUKAGAWA A et al.: 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89-97.
8. 1 receptor. Proc. Natl. Acad. Sci. USA (2001) 98:3662-3665.
9. 1 receptor. J. Pharmaocol. Exp. Ther. (2002) 301:1020-1024.
10. CROXFORD JL: Therapeutic potential of cannabinoids in CNS disease. CNS Drugs (2003) 17:179-202.
11. DI MARZO V, FONTANA A, CADAS H et al.: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372:686-691.
12. CRAVATT BF, GIANG DK, MAYFIELD SP, BOGER DL, LERNER RA, GILULA NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 384:83-87.
13. DEUTSCH DG, GLASER ST, HOWELL JM et al.: The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J. Biol. Chem. (2001) 276:6967-6973.
14. GOYA P, JAGEROVIC N: Recent advances in cannabinoid receptor agonists and antagonists. Expert Opin. Ther. Patents (2000) 10 1529-1538.
15. ADAM J, COWLEY P: Recent advances in the cannabinoids. Expert Opin. Ther. Patents (2002) 12:1475-1489.
16. PERTWEE RG: Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin. Investig. Drugs (2000) 9 1553-1571.
17. HOWLETT AC, BARTH F, BONNER TI et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. (2002) 54:161-202.
18. 1 cannabinoid receptor antagonists. Curr. Opin. Drug Discov. Dev. (2004) 7 498-506.
19. FOWLER CJ, JACOBSON SO: Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide - targets for drug development? Prostaglandins, Leukot. Essent. Fatty Acids (2002) 66:193-200.
20. LOPEZ-RODRIGUEZ ML, VISO A, ORTEGA-GUTIERREZ S, FERNANDEZ-RUIZ J, RAMOS JA: Endocannabinoid transporter inhibitors. Curr. Med. Chem. Central Nervous System Agents (2002) 2:129-141.
21. CRAVATT BF, LICHTMAN AH: Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr. Opin. Chem. Biol. (2003) 7:469-475.
22. RINALDI-CARMONA M, BARTH F, HEAULME M et al.: SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. (1994) 350:240-244.
23. NAKAMURA-PALACIOS EM, MOERSCHBAECHER JM, BARKER LA: The pharmacology of SR141716A: a review. CNS Drug Rev. (1999) 5 43-58.
24. 1 receptor antagonists related to SR141716. Bioorg. Med. Chem. Lett. (2004) 14:1151-1154.
25. 1 cannabinoid receptor antagonists. J. Med. Chem. (2004) 47:627-643.
26. BELL MR, D'AMBRA TE, KUMAR V et al.: Antinociceptive (aminoalkyl) indoles. J. Med. Chem. (1991) 34:1099-1110.
27. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc. Natl. Acad Sci. USA (2003) 100:10529-10533.
28. GLASER ST ABUMRAD NA, FATADE F, KACZOCHA M, STUDHOLME KM, DEUTSCH DG: Evidence against the presence of an anandamide transporter. Proc. Natl. Acad. Sci. USA (2003) 100:4269-4274.
29. CRAVATT BF, DEMAREST K, PATRICELLI MP et al.: Supersensitivity to anandamide and endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA (2001) 98:9371-9376.
30. KATHURIA S, GAETANI S, FEGLEY D et al.: Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. (2003) 9:76-81.
31. BOGER DL, SATO H, LERNER AE et al.: Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. USA (2000) 97:5044-5049.
32. American College of Cardiology Meeting, New Orleans, March 2004.
33. Analysts' Meetings, Sanofi-Synthelabo, 4 September 2001 and September 2002.
34. Company presentation, Sanofi-Synthelabo, 16 February 2004.
35. Aventis 2003 Full Year Results Meeting, 5 February 2004, London, UK.
36. 2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 93 239-245.
37. 2 cannabinoid receptors. Anesthesiology (2003) 99:955-960.